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ABSTRACT 
Background: Cancer induced hypercalcemia (CIH) is the most frequent metabolic oncologic 
emergency and occurs in up to 44.1% of all cancer patients at some time in their disease 
course. It occurs in patients with both solid and hematologic malignancies. CIH occurs 
mostly in patients with advanced cancer and is an indicator of poor prognosis. Timely 
diagnosis and intervention is lifesaving and also may enhance patient compliance with 
primary and supportive treatment and quality of life. This study aimed to describe the 
incidence, clinical patterns and treatment outcomes of hypercalcemia in cancer patients 
receiving Radiation therapy in Charlotte Maxeke Johannesburg Academic Hospital, 
Johannesburg.  
Materials and Methods: This was a retrospective descriptive study, 125 patients who were 
admitted at the Radiation oncology ward CMJAH for hypercalcemia management from 
January 2012 to December 2015, were analyzed. Demographic data, relevant clinical 
information such as Stage of the disease, type of cancer, level of hypercalcemia, toxicity and 
Response to the treatment were recorded. Statistical analysis was performed using the 
Statistical Package for the Social Sciences (SPSS_version 23). The incidence of 
hypercalcemia, clinical patterns, treatment outcomes and toxicities were evaluated. The 
study was approved by the Human Research Ethics Committee medical (HRECM) of the 
University of Witwatersrand with Clearance certificate number M140546. 
Results: Of the 125 patients analysed, males to females ratio was 1:1. The most frequent 
site of primary cancer diagnosis in patients with hypercalcemia was gynaecological 
malignancies 31 (24.8%), followed by head and neck cancers 23 (18.4%), prostate 19 
(15.2%), breast cancer 17 (13.6%), gastrointestinal malignancies 12 (9.6%), multiple 
myeloma 5 (4%), lung cancer 3 (2.4%) and other malignancies 15 (12%). Most patients had 
metastatic disease and uncontrolled primary disease 78 (62.4%) compared to primary 
controlled disease 47 (37.6%). Bone metastasis were present in 51 (41%) of patients.  
Clinical presentation of patients with hypercalcemia was mainly Neuromuscular 41 (32.8%), 
nausea/vomiting 37 (29.6%), Polyuria 20 (16%), mental 16 (12.8) and Polydipsia 9 (7.2%). 
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Most of patients had severe hypercalcemia with pre-treatment corrected serum calcium 
level of > 2.9 mmol/L 77 (61.6%), 28 (22.4%) had Corrected serum Calcium between 2.71-
2.89 mmol/L and 20 (16%) had corrected serum calcium between 2.56-2.70 mmol/L. One 
hundred and four patients (83.2%) received hydration + bisphosphonates and 21 (16.8%) of 
patients received hydration alone and non-received haemodialysis.   
One week post treatment majority of patients had ≤2.55 mmol/L Serum level of Calcium 81 
(64.8%), 11 patients (8.8%) had serum level of calcium 2.56-2.71 mmol/L, 23 patients 
(18.4%) had serum calcium between 2.71-2.89 mmol/L and only 10 patients (8.0%) had 
serum level of calcium ≥2.9 mmol/L. The corrected serum calcium was 2.4770 ± 0.34512 
mmol/L one week after treatment. 
One month post treatment majority of patients 99 (79.2%) remains to have normal serum 
level of calcium ≤2.55 mmol/L and only about 11 (8.8%) patients had ≥2.9 mmol/L. 
Forty four patients (35.2%) had relapse in 33 days (median) time and were subsequently 
treated with hydration and bisphosphonates. As the patients were enrolled from radiation 
oncology ward, most were treated with either radiation alone 72 (57.6%) or Concurrent 
chemo radiation 15 (12.0%) as treatment modalities for their primary cancer. Patients who 
received chemotherapy first and then radiotherapy for the treatment for their primary 
cancer were 37 (29.6%).  
Fourteen (58%) patients with pre-treatment calcium level of 2.56-2.70 mmol/L received 
hydration alone and 76 (98%) of patients with serum pre-treatment calcium of ≥2.9 mmol/L 
were treated with hydration + bisphosphonates (P=0.001). Side effects to bisphosphonates 
were mainly gastrointestinal: Nausea/vomiting 42 (33.6%) patients, Constipation 14 (11.2%), 
abdominal pain 13 (10.4), Diarrhoea 11 (8.8) and anorexia 1 (0.8) patients. Other toxicities 
reported were fever 12 (9.6%) patients and hypocalcaemia 14 (11.2%). Eighteen patients 
(14.4%) did not report any side effect to treatment. 
Conclusion: Hypercalcemia of malignancy is a common finding in patients with advanced 
stage cancers. Hypercalcemia of malignancy usually presents with markedly elevated 
calcium levels and patients are therefore usually symptomatic. For acute management of 
hypercalcemia, rehydration is the mainstay of treatment because all patients tend to have 
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dehydration. Bisphosphonates are potent calcium lowering agents, but they require careful 
administration and are contraindicated in patients with declined renal function. Common 
bisphosphonates toxicities are mainly gastrointestinal: Nausea/vomiting, constipation, 
abdominal pain, diarrhoea and anorexia. Other toxicities reported were fever and 
hypocalcaemia.   
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CHAPTER ONE 
1.0. Introduction and background 
Hypercalcemia is defined as an increased serum calcium level above the normal upper limit 
for a given reference value used in a laboratory (1, 4). Cancer induced hypercalcemia (CIH) 
and primary hyperparathyroidism are the most and second most common causes of 
hypercalcemia in hospital in-patients, respectively (1, 5, 6).  
Cancer induced hypercalcemia (CIH) is the most frequent metabolic oncologic emergency 
and occurs in up to 44.1% of all cancer patients at some time in their disease course (2, 4, 7). 
It occurs in patients with both solid and hematologic malignancies. Types of cancer 
commonly associated with CIH include Squamous cell carcinoma of the lung, head and neck, 
and esophagus; multiple myeloma; renal cell carcinoma; ovarian carcinoma and lymphoma. 
Lung cancer, breast cancer and multiple myeloma have the highest incidence of CIH, 
accounting for more than 50%, while the condition occurs rarely in patients with colorectal 
carcinoma (8, 9). More than 30% of patients with multiple myeloma, 25% of those with 
squamous cell carcinoma and 20% of those with breast cancer may develop CIH (10). 
Tumors rarely associated with CIH include central nervous system malignancies and prostate 
cancer, as well as stomach and colorectal adenocarcinoma (8).  
Cancer induced hypercalcemia (CIH) is particularly common in patients with advanced 
cancer (20-40%) and is an indicator of poor prognosis with a mean survival rate of 2-3 
months (3, 11). The extent of metastatic bone disease correlates poorly with both the 
occurrence and severity of CIH (46).  Patients with CIH tend to have limited survival of 
several months (12).  
Timely diagnosis and intervention is lifesaving and also may enhance patient compliance 
with primary and supportive treatment and quality of life (2). 
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1.1. Normal Regulation of Calcium Metabolism 
Calcium is important in biochemical reactions such as muscle contraction, bone 
development and coagulation among others (13). Approximately 10-20% of ingested 
calcium is absorbed in the small intestine (13). Calcium is present in two major 
compartments: Bone (major part of body calcium) and plasma (13). In plasma, serum 
calcium is present in several forms, such as free or ionized calcium, which is actually a 
physiologically active form corresponding to approximately 45% of serum calcium, with 65% 
of calcium being bound to various carriers, such as albumin (40% of calcium), citric acid, 
sulfate, and phosphate (13). 
Calcium absorption and metabolism is regulated by several hormonal mechanisms. When 
calcium levels drop below 2.5 mmol/L, this activates calcium-sensing cells in the parathyroid 
glands to stimulate the release of Parathyroid Hormone (PTH) (13). 
When PTH is released, it activates the 1-alpha-hydroxylase enzyme located in the renal 
proximal tubules, which converts 25-hydroxyvitamin D into active form 1,25-
dihydroxyvitamin D (7).  PTH also stimulates calcium reabsorption in the distal part of the 
nephron and renal phosphorus excretion. Calcium is then mobilized from the bone with the 
help of 1,25-dihydroxyvitamin D. All these leads to an increase in serum calcium 
concentrations and bringing them back to normal (13). 
Vitamin D is another key player in normal calcium metabolism. When converted to its active 
form 1,25-dihydroxycholecalciferol in the liver and kidneys, it increases the absorption of 
calcium and phosphate in the gastrointestinal tract, decreases the renal excretion of calcium 
and phosphate, and with the participation of PTH leads to increased calcium release from 
the bone and subsequent bone de-mineralization (13).  
Calcitonin, a thyroid hormone produced by thyroid C cells is also important in calcium 
normal physiology. When calcium concentration increases the calcitonin release is 
augmented which limits bone remodeling and calcium release from the bone and also 
calcium reabsorption in the kidneys (14). 
In conclusion, interaction between calcium levels, PTH, Vitamin D, and bone cells regulates 
bone metabolism and calcium release from the bones. 
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1.2. Etiology and pathophysiology of Cancer induced hypercalcemia. 
Three major mechanisms by which CIH can be mediated are; tumor secretion of parathyroid 
hormone-related protein (PTHrP) also known as Humoral hypercalcemia of malignancy 
(80%); osteolytic metastases (20%) with local release of cytokines (including osteoclast 
activating factors); and tumor production of 1,25-dihydroxyvitamin D (calcitriol) (1,3) 
(Table1).  
Table 1: Mechanisms of Hypercalcemia of Malignancy 
Mechanism Malignancies Frequencies (%) 
PTHrP production Squamous cell carcinomas: lung, cervical, 
esophageal, oral and laryngeal cancers 
Certain lymphomas: non-Hodgkin’s, T-cell 
lymphoma 
Adenocarcinomas: breast and ovary 
Renal cell carcinoma 
Transitional cell carcinoma 
Multiple myeloma (rare)  
           80 
Local Osteolysis Multiple myeloma (frequent) 
Solid malignancies: breast, prostate and lung 
cancers. 
Lymphomas 
           20 
Secretion of 1,25-
dihydroxyvitamin D 
(calcitriol) 
Multiple myeloma 
Lymphomas: Hodgkin’s, non-Hodgkin’s 
 
 
The cellular basis for the former two mechanisms includes changes in the activity and 
balance at the level of the bone-remodeling unit. Bone turnover involves the highly 
coordinated activity of two distinct types of cells, the osteoblast, or bone-forming cell and 
the osteoclast, or bone-removing cell (3, 15). Communication between osteoblasts and 
osteoclasts primarily involves the receptor activator of nuclear factor k B (RANK) ligand 
(RANKL) signaling pathway (3, 15).  
RANK is a receptor expressed on osteoclast precursor cells. The naturally occurring ligand, 
RANKL, is produced by osteoblasts and drives proliferation and differentiation of the 
osteoclasts into mature, multinucleated units. In addition, the osteoblast cell produces 
osteoprotegerin (OPG), a decoy receptor that binds to and inactivates RANKL (3, 15). 
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Osteoblast is the focal point for the integration of endocrine and paracrine signals that alter 
bone remodeling. Osteoblast cells express estrogen receptors that when occupied with 
ligand can reduce RANKL and increase OPG (3, 15). Osteoblasts also express the cell surface 
receptor for parathyroid hormone (PTH) and parathyroid hormone–related hormone 
(PTHrP), PTH1R (3, 15). Both PTH and PTHrP stimulate PTH1R, which, in turn, increases 
osteoblast activity and RANKL signalling to the osteoclast. In sum, PTH/PTHrP signaling 
results in an increased bone turnover with a greater increase in bone resorption than 
formation, resulting in a net efflux of calcium and hypercalcemia from the bone 
microenvironment (see Figure 1). 
 
 
 
Figure 1: Interactions between osteoclasts and cancer cells 
Tumors that commonly produce PTHrP include squamous cell carcinomas of the lung, cervix, 
and esophagus; certain lymphomas; renal cell carcinoma; and adenocarcinoma of the 
breast, prostate, and ovary (16).  
The second mechanism by which malignancies cause hypercalcemia includes osteolytic 
metastases and excessive calcium release from bone, accounting for approximately 20% of 
malignancy-related hypercalcemia (3). Local osteolysis as the basis for hypercalcemia occurs 
most frequently in widely metastatic disease (eg; breast and lung cancers), and the degree 
of hypercalcemia correlates with the extent of tumor burden (3).  
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Multiple myeloma also present with significant areas of osteolysis and hypercalcemia (17). 
Underlying the release of calcium from the bone microenvironment is increased osteoclast 
activity, probably due to PTHrP and other factors that can increase resorption (17). 
The third mechanism includes ectopic activity of 1-alpha-hydroxylase and the formation of 
1,25-dihydroxycholecalciferol. Vitamin D enhances calcium and phosphate absorption from 
the intestinal tract. Stored vitamin D (25-[OH]D) is 1-hydroxylated in the kidney to the active 
compound 1,25- (OH)2D. PTH actively drives the 1-hydroxylase step at the kidney (18). 
Patients with Hodgkin lymphoma, non-Hodgkin lymphoma, as well as multiple myeloma, 
have been described as having vitamin D–mediated hypercalcemia (18). In these patients, 
1,25-(OH)2D levels, along with calcium levels, are high while PTH is suppressed from the 
negative feedback to the parathyroid cells. Similarly, measurements of bone turnover 
markers are low in vitamin D–mediated hypercalcemia because the reduction in PTH results 
in a diminution of osteoblast and osteoclast activity (18). 
 
1.3. Diagnosis 
Hypercalcemia may be classified based on total serum and ionized calcium levels, as follows: 
Normal serum calcium levels are 2.0 to 2.55 mmol/L (see Figure 2).  Hypercalcemia is 
considered mild if the total serum calcium level is between 2.56 and 3 mmol/L. Levels higher 
than 3.5 mmol/L can be life threatening (19).  
Hypercalcemia was defined as serum calcium higher than 2.55 mmol/L which is the upper 
normal limit of serum calcium measurement for the central laboratory at CMJAH-
Johannesburg, after correction with serum albumin using the following formula:  
Corrected serum calcium = measured serum calcium + [(4-serum albumin) x 0.8]. 
After treatment, patients who had corrected serum calcium of less than 2.55 mmol/L were 
defined as responders. 
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Figure 2: Spectrum of hypercalcemia indicated by serum total and ionized calcium levels. 
 
1.4. Clinical presentation of Hypercalcemia of Malignancy. 
The clinical manifestations of hypercalcemia are generally constitutional in nature, non-
specific, and independent of etiology (20). 
The degree of CIH, along with the rate of rise of serum calcium concentration, often 
determines symptoms and the urgency of therapy (1, 2). Patients with mild hypercalcemia 
(Ca2+ < 3 mmol/L) may be asymptomatic, or they may report vague or nonspecific 
symptoms, such as constipation, fatigue, and depression. A serum calcium of (3 to 3.5 
mmol/L) may be well-tolerated chronically, while an acute rise to these concentrations may 
cause marked symptoms, including polyuria, polydipsia, dehydration, anorexia, nausea, 
muscle weakness, and changes in sensorium. In patients with severe hypercalcemia (calcium 
>3.5 mmol/L), there is often progression of these symptoms (2) (Table 2). 
Neurocognitive symptoms may include some behavioral disturbances, such as anxiety, 
mood changes and a decrease in cognitive function. In cancer patients with higher values of 
calcium, they may develop more severe presentations, such as changes in mental status, 
including coma (21). 
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Renal manifestations of hypercalcemia consist of nephrogenic diabetes insipidus with 
resultant polyuria, renal vasoconstriction, distal renal tubular acidosis, and in more chronic 
cases, nephrolithiasis, tubular dysfunction, and chronic renal failure (22, 23).  
Hypercalcemia also affects the gastrointestinal system. Mild hypercalcemia may present as 
anorexia and constipation (24). Patients with more advanced hypercalcemia may develop 
nausea and vomiting. 
Cardiovascular system may also be affected by elevated calcium. Patients with 
hypercalcemia typically have a shortened QT interval on the electrocardiogram (ECG) (25). 
Severe hypercalcemia may mimic ST-segment elevation myocardial infarction on the ECG 
(25). Patients with severe hypercalcemia may develop malignant ventricular arrhythmias 
such as ventricular fibrillation (26).  
Table 2: Clinical Manifestations of Hypercalcemia of Malignancy 
Symptoms  Signs 
General 
Fatigue, lethargy, pruritis 
 
Dehydration 
Cardiac  
Palpitations 
 
Atrial arrhythmias, ventricular arrhythmias, 
shortened QT interval, prolonged PR 
interval, Bradycardia  
Neurologic  
Muscle weakness, confusion 
 
Hyporeflexia, obtundation, pyschosis, 
seizure, coma 
Gastrointestinal  
Nausea, vomiting, constipation 
 
Internal ileus, distension 
Renal 
Polyuria 
 
Renal failure 
Skeletal 
Bone pain 
 
Bone fracture 
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1.5. Management of Cancer induced hypercalcemia 
The management of CIH is based on the presence of symptomatology and the severity of 
calcium elevation. Patients with asymptomatic or mildly symptomatic (eg, constipation) 
hypercalcemia (Below calcium 3 mmol/L) do not require immediate treatment. Similarly, a 
serum calcium of 3 to 3.5 mmol/L may be well-tolerated chronically, and may not require 
immediate treatment. However, an acute rise to these concentrations may cause marked 
changes in sensorium, which requires more aggressive measures. In addition, patients with 
a serum calcium concentration 3.5mmol/L require treatment, regardless of symptoms (44).  
Management of CIH includes hydration, calcitonin, bisphosphonates, denosumab, and in 
certain patients, prednisone and cinacalcet. Hemodialysis should be considered in patients 
with advanced underlying kidney disease and refractory severe hypercalcemia (37, 38, 39). 
The first step of management of CIH should be to assess the hydration status and saline 
infusion is currently the standard of treatment, depending upon the severity of dehydration. 
Hydration alone may be sufficient for asymptomatic patients with borderline serum calcium 
(37). Adequate hydration reduces serum calcium by a medium of 0.25 mmol/L (38).  
Start patients with advanced hypercalcemia at a rate of around 200-300 ml/h and reassess 
them periodically for signs of fluid overload (shortness of breath, edema, etc.). Re-hydration 
with 2 to 3 litres per day is now the accepted practice with daily serum electrolyte 
measurement to prevent hypokalemia and hyponatremia for cases of severe or 
symptomatic hypercalcemia (37, 39). Increase patient’s oral fluid intake to 2 to 3 litres per 
day, as tolerated (37).  
The rate of IV hydration should be decreased in patients with underlying cardiac and renal 
disease to minimize the risk of symptomatic fluid overload. Loop diuretics (i.e. furosemide, 
20 to 40 mg IV, every 2 hours) enhance calcium excretion only after normovolemia has been 
reached but the routine use is not recommended due to the development of volume 
depletion and electrolyte abnormalities. Thiazide diuretics should be avoided, as they 
worsen hypercalcemia (27).  
Bisphosphonates (BP) represent at present the drugs of choice for treating patients with 
CIH. They work by inhibiting osteoclasts, inducing apoptosis in these cells and bind to bone, 
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blocking osteoclastic resorption and osteolysis. Once inside osteoclasts, BPs hamper 
adhesion to the mineralized matrix, reduce lysosomal enzymes and activate a pro-apoptotic 
pathway (3). 
Bisphosphonates are appropriate to administer when serum calcium (corrected) is greater 
than or equal to 3 mmol/L or when serum calcium (corrected) is less than 3 mmol/L when 
accompanied by symptoms (38). 
Bisphosphonates (BPs) effectively lower the serum calcium level with maximum effect seen 
in 2 to 4 days. The duration of effect is usually several weeks and varies among patients and 
with the type of BP. Patients treated with BP have a delayed time to skeletal fracture, and a 
reduced need for radiation therapy and orthopedic surgery to treat bone metastases (3). 
Bisphosphonates (BPs) are subdivided into two groups: First and second-generation BPs. 
The first-generation or non-nitrogen-containing bisphosphonates include etidronate and 
clodronate, which are less commonly used nowadays. The second generation or nitrogen-
containing bisphosphonates include such medications as alendronate, risedronate, 
ibandronate, pamidronate, and zoledronic acid, which are generally more potent than the 
first-generation bisphosphonates (27, 28). 
Pamidronate is able to normalize calcium levels in 80% to 100% of patients and the infusion 
time of 2-4 hours does not show a significant increment of nephrotoxicity (1, 27). 
Randomized trials have proved that pamidronate is superior to clodronate, etidronate and 
mithramycin (1, 27). 
Zoledronate is a second-generation BP and can be administered in a dose 10 times lower 
than pamidronate (1, 27). It has been shown to be superior to pamidronate in the rate of 
normocalcemia, duration of control of CIH and time to relapse (1 to 1.5 months) (50). The 
rate of normalizing serum calcium is significantly higher for zoledronic-acid-treated patients 
(88.4% for 4 mg and 86.7% for 8 mg) than for pamidronate disodium-treated patients 
(69.7%) (50). It is given in a 15-minute IV infusion (4 mg), and it is approved for use only in 
the CIH, while higher doses can be used in relapsing or refractory patients (1, 27).  
 10 
 
Its use is contraindicated if creatinine clearance is below 30 ml/min and/or if other 
nephrotoxic drugs are administered to the patient (1, 27). Fever is a common side effect of 
zoledronic acid, with renal impairment seen rarely (40).  
Pamidronate is given by IV infusion over 4 to 24 hours. The initial dose varies: 30 mg if the 
Ca2+ < 3 mmol/L, 60 mg if the Ca2+ is 3-3.5 mmol/L and 90 mg if the calcium level is even 
higher level. A subsequent dose should not be given until after 7 days. Because of the lag in 
onset of effect, BPs should be combined with faster acting therapeutic modalities, such as IV 
saline infusion and calcitonin injections. Pamidronate is effective in normalizing serum 
calcium levels in 80%-94% of patients (49). 
Ibandronate is another BP useful in patients with breast or hematological cancer (29). A 
randomized trial comparing ibandronate and pamidronate showed a comparable activity of 
the two drugs in reducing calcium levels, while the median duration of response appeared 
to be longer for ibandronate (30). Ibandronate significantly lowered serum calcium levels in 
up to 77% of patients after 5 days (47, 48). The dose of ibandronate is 150 mg orally once 
monthly. The tablet should be taken on the same day of each month. It has an extremely 
low rate of nephrotoxicity and no dose reductions are needed for patients with moderate 
renal impairment or those treated with concomitant nephrotoxic therapies (29).  
Bisphosphonates side effects include flu-like symptoms, ocular symptoms, acute kidney 
injury, new-onset nephrotic syndrome, esophageal inflammation (typically for orally 
administered drugs), and very rarely osteonecrosis of the jaw (28). Osteonecrosis of the jaw 
is mostly reported in patients with multiple myeloma or metastatic bone disease receiving 
high potency bisphosphonates, such as zoledronic acid and denosumab, which is a 
monoclonal antibody to RANKL (32). 
Denosumab is the human monoclonal antibody able to interfere with RANKL-RANK 
pathways (31). This agent showed a rapid and sustained dose-dependent decrease of bone 
turnover, when administered to postmenopausal osteoporotic women. Denosumab is 
superior to zoledronic acid in preventing skeletal related events (SRE) with favorable safety 
and convenience in patients with bone metastases from advanced cancer (31).  
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Denosumab has been shown to be effective in hypercalcemia refractory to bisphosphonates 
(33). The dose is 120 mg subcutaneously, and it should be repeated no earlier than 7 days 
following the first administration (34). Its effects are seen within 2-4 days after the 
administration. 
Common side effects of denosumab include bone pain, nausea, diarrhea, shortness of 
breath, and in rare instances osteonecrosis of the jaw, which is usually seen in patients 
treated with denosumab for at least several months (5, 35). 
There were many other treatments used in CIH before the advent of BPs, including 
corticosteroids, calcitonin, plicamycin, and gallium nitrate (3).  
Steroids are particularly useful for hypercalcemia seen with lymphomas and multiple 
myeloma (40). Corticosteroids may lower serum calcium if they have an antineoplastic 
effect on the underlying malignancy (38). They should be reserved for situations in which 
bisphosphonates are not easily accessible or are ineffective or in which other indication for 
corticosteroids (pain or nausea) exist (38). Doses of steroids commonly used are prednisone 
40 to 100 mg daily for up to one week (37); hydrocortisone 100 mg I.V. q6h (42); and  
dexamethasone 4 mg S.C. q6h for 3 to 5 days (42).  
Calcitonin is rarely used, despite the fact that it works rapidly, because its effect is short 
lived (2 to 3 days); repeated doses of calcitonin are less effective because patients develop 
tolerance to the calcium-lowering effect due to the down regulation of calcitonin receptors 
in osteoclasts. Calcitonin can be used initially with BPs in cases of severe symptoms and very 
high calcium levels to incur a rapid response and allow time for the BPs to work. The usual 
dose of calcitonin is 100units subcutaneously 3 times a day for 1 to 2 days (3). Possible side 
effects: flushing, mild nausea, crampy abdominal pain. A small risk of hypersensitivity exists 
due to salmon derivation (38). 
Gallium nitrate is rarely used because it has nephrotoxicity and its infusion takes 5 days 
continuously (3). 
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In conclusion, the first step of therapy in CIH patients is to restore renal function which is 
often impaired due to dehydration. Enhanced bone resorption represents the main cause of 
CIH and thus the second step is bisphosphonates administration. Bisphosphonates should 
be administered concurrently as the hypocalcemic effect starts within 2-4 days. 
Pamidronate, zoledronate and ibandronate are at present the main-stay of treatment. 
Calcitonin can be used given its prompt effect and favorable side-effect profile. Other non-
bisphosphonates drugs have limited activity and several side-effects. Patients with 
refractory hypercalcemia should be considered for denosumab therapy and lastly for 
hemodialysis (Table 3). 
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Table 3: Therapeutic options for the management of Cancer induced Hypercalcemia. 
 
Agent 
 
Mechanisms  
of action 
 
Cautions 
 
Onset of 
action 
 
Duration 
 
Side effects 
 
 
Normal saline 
(0.9% Sodium 
chloride) 
200-400ml/hr  
2-4 L IV/day 
Volume 
repletion, 
increased 
renal Ca2+  
clearance 
Consider lower rate in patients 
with underlying renal disease 
Immediate 2-3 days Volume 
overload, 
non-
aniongap 
metabolic 
acidosis 
 
 
Calcitonin 
4-8 units/kg SQ q 
6-12 hours 
Inhibits bone 
resorption, 
augments 
Ca++ excretion 
Rebound ↑Ca2+ after 24 
hours, vomiting, cramps, 
flushing, Rapid ↑Ca2+ within 
2 to 6 hours 
4-6 hours Up to 3 
days 
Nausea, 
rhinitis, 
hypersensitiv
ity 
reactions 
 
 
Bisphosphonates 
Zoledronic acid 
4mg administered 
IV over 15 min; 
Pamidronate 60-
90mg 
administered IV 
over 2-24 h; 
Ibandronate 2-6 
mg administered 
IV over 1-2 h 
Inhibition of 
osteoclast 
activity, 
osteoclast 
apoptosis and 
improved 
osteoblast 
survival 
Zoledronic acid: Do not use in 
patients with creatinine >4.5 
mg/dl; no need for hepatic  
adjustment 
Pamidronate and ibandronate: 
Do not use if glomerular 
filtration rate is <30; no need 
for hepatic adjustment 
Within 2-4 
days after 
administrat
ion. Can be 
repeated 
after 7 days  
3-4 weeks Flu-like 
symptoms, 
nephrotic 
syndrome,  
acute kidney 
injury, 
osteonecrosi
s of the jaw 
 
 
 
 
 
Denosumab 
120mg SQ weekly 
for 4 weeks, then 
monthly 
thereafter 
Impairs 
osteoclast  
activity 
No need for renal and hepatic 
adjustment. 
Consider half dose for patients 
with renal disease to decrease 
the risk of hypocalcemia 
Within 2-4 
days after 
administrat
ion. Can be 
repeated 
after 7 days  
3-4 
months 
Bone pain, 
nausea, 
diarrhea, 
shortness of 
breath, 
osteonecrosi
s of the jaw  
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1.6. Objectives of the study 
1.6.1. Broad Objective 
The broad objective of the study was to describe the management of hypercalcemia in 
patients with malignancies receiving Radiation therapy at CMJAH, Johannesburg from 
January 2012 to December 2015.  
1.6.2. Specific objectives 
The specific objectives/endpoints of this study were; 
1. To study the incidence of types of malignancies associated with hypercalcemia and 
its correlation with stage of disease in patients receiving Radiation therapy at              
CMJAH, Johannesburg from January 2012 to December 2015. 
2. To describe the treatment strategies used for hypercalcemia in cancer patients 
receiving radiation therapy at CMJAH, Johannesburg from January 2012 to 
December 2015. 
3. To assess the effectiveness of bisphosphonates in control of Hypercalcemia in cancer 
patients receiving Radiation therapy at CMJAH, Johannesburg from January 2012 to 
December 2015. 
4. To assess the toxicity of treatment with bisphosphonates in cancer patients receiving 
radiation therapy at CMJAH, Johannesburg from January 2012 to December 2015. 
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CHAPTER TWO 
2.0. Materials and methods 
2.1. Study design 
This was a retrospective descriptive study; all cancer patients with hypercalcemia who were 
admitted at the Radiation oncology ward CMJAH for hypercalcemia management from 
January 2012 to December 2015 were included in the study and the data was collected by 
reviewing hospital folders from the hospital archives. The relevant information from files 
was recorded on a data collection form (proforma). 
2.2. Study site/area 
This study was conducted in the Radiation oncology department/ward at the Charlotte 
Maxeke Johannesburg Academic Hospital (CMJAH). CMJAH is an accredited central tertiary 
care academic hospital with 1088 beds serving patients from across the Gauteng province 
and neighboring provinces. It is estimated to have more than 4000 professional and support 
staff offering a full range of specialized services to inpatients and outpatients. 
It is located in Parktown and serves as a referral hospital for a number of hospitals in its 
referral chain. The hospital is also a major teaching hospital for The University of the 
Witwatersrand, Faculty of Health Sciences for undergraduate and post-graduate training in 
all areas of health professions (36). 
Radiation oncology department of the CMJAH is the only radiation center owned by state in 
Johannesburg, and it acts as a referral center for all hospitals in Johannesburg. Radiation 
Oncology Unit is the largest in the country and treats about 3 500 patients a year (36). 
2.3. Study population 
The study reviewed medical records of all cancer patients with hypercalcemia admitted to 
the Radiation oncology ward at Charlotte Maxeke Johannesburg Academic hospital from 
January 2012 to December 2015 and assessed for eligibility criteria. 
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2.4. Inclusion criteria 
The study included medical records of cancer patients with hypercalcemia admitted to the 
Radiation oncology ward at CMJAH from January 2012 to December 2015. 
Inclusion criteria: 
1. Diagnosis of malignancy 
2. Hypercalcemia, corrected calcium > 2.56mmol/l 
3. Patient receiving or received radiotherapy 
Exclusion criteria:  
1. Age below 18 and Above 70 years 
2. Patients that never received radiotherapy 
 
 2.5. Sampling and sample size 
All patients admitted in the Radiation Oncology ward CMJAH for the management of 
hypercalcemia were included in the study. 
A total number of 125 patients’ files for the period of 4 years from January 2012 to 
December 2015 were available for review. 
2.6. Data Management 
2.6.1 Data collection  
Each file was given a code according to the order of admission, and this code was used to 
link the data entered into the Excel sheet, and identifying details were removed so that the 
data remained anonymous and confidential. 
The following data were collected from the patients’ records: demographic information, 
Primary cancer diagnosis, stage, its presentation and treatment of primary tumor, presence 
of bone metastasis, clinical presentation, investigations done, pretreatment serum 
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(baseline) corrected Ca2+, and treatment of hypercalcemia given. Data on the outcome 
after treatment were also recorded, including 1 week and month post treatment corrected 
Ca2+, symptom relief, relapse and subsequent treatment given after relapsed. Information 
on type of hypercalcemia treatment given and its toxicity were also recorded.   
The above information was recorded using data collection form (see Appendix A).  
 
2.6.2. Data analysis  
Participants’ information was captured into an MS-Excel spread sheet. Data cleaning was 
done to check for missing values, any inconsistencies, and to identify any extreme values. 
After data cleaning, the MS-Excel spreadsheet was then imported to statistical software 
(SPSS_version 23) IBM, Armonk, NY for descriptive analysis purposes. Standard statistical 
methods were used. Categorical data was described using frequencies and percentages. The 
distribution of continuous variables was determined. These were then described using 
measures of central tendency: mean ± standard deviation for normally distributed data; and 
median and interquartile range for skewed data. A P-value of less than 0.05 was considered 
significant. 
2.7. Ethical Consideration 
Ethics approval was obtained from the Human Ethics Research Committee of the University 
of the Witwatersrand, which issued certificate number M140546 (see Appendix B). 
Institutional approval was obtained from the Chief Executive Officer of CMJAH (see 
Appendix C). 
Only serial numbers were used to all patients’ files reviewed in the study to maintain 
confidentiality. 
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CHAPTER THREE 
3.0. Results 
3.1. Descriptive analysis 
3.1.1. Demographic characteristics of the study participants. 
A retrospective chart review was conducted over a period of four years and a total number 
of 125 cancer patient records admitted for management of hypercalcemia from January 
2012 to December 2015 were retrieved. 
Mean age was 52.31 years ± 11.388 SD, with the youngest patient being 28 years old and 
the oldest being 70 years (Table 4). Sixty three (50.4%) patients were male, and 62 (49.6%) 
were female (Table 5).  
Table 4: Age  
 Age   (years) 
Minimum 
Maximum 
Mean 
Std. Deviation 
28 
70 
52.31 
11.388 
                
Table 5: Sex                                  
 Frequency Percentage (%) 
Male  
Female 
Total 
63 
62 
125 
50.4 
49.6 
100 
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3.1.2. Site of primary Cancer diagnosis  
The most frequent site of primary cancer diagnosis in patients with hypercalcemia were 
gynecological malignancies 31(24.8%), head and neck 23(18.4%), prostate 19(15.2%), breast 
cancer 17(13.6%), gastrointestinal malignancies 12(9.6%), multiple myeloma 5(4%) and lung 
cancer 3(2.4%), (Table 6). 
Table 6: Cancer diagnosis and relative prevalence of hypercalcemia   
Diagnosis/ site Number of patients Percentages (%) 
Lung cancers 
Breast cancer 
Head and neck cancers 
Multiple myeloma 
Gynaecological cancers 
Prostate cancer  
GIT malignancies 
Others 
3 
17 
23 
5 
31 
19 
12 
15 
2.4 
13.6 
18.4 
4.0 
24.8 
15.2 
9.6 
12.0 
 
3.1.3. Presentation of Cancer diagnoses 
Most patients had metastatic disease 46(36.8%) and uncontrolled primary disease 
32(25.6%) compared to primary controlled disease 47(37.6%), (Table 7).  
Table 7: Presentation of Cancer diagnoses 
Presentation Number of patients Percentage (%) 
Primary controlled 
Primary  uncontrolled 
Metastatic  disease 
47 
32 
46 
37.6  
25.6  
36.8  
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3.1.4. Presence of Bone metastasis 
Bone metastases were present in 51(41%) patients and absent in 74(59%) patients (Table 8). 
 
Table 8: Presence of Bone metastasis 
 Number of patients  Percentage (%) 
Present     
 
Absent      
            51  
 
            74  
41    
       
59 
 
 
3.1.5. Clinical presentation of patients with hypercalcemia 
All patients presented with symptoms related to hypercalcemia. The most frequent clinical 
symptoms were Neuromuscular 41(32.8%), nausea/vomiting 37(29.6%), Polyuria 20(16%), 
mental 16(12.8) and Polydipsia 9(7.2%), (Table 9). 
 
Table 9: Clinical manifestations of hypercalcemia in patients receiving radiotherapy.  
Clinical manifestations Number of patients   Percentages (%) 
Nausea/vomiting 
Polyuria 
Polydipsia 
Constipation 
Neuromuscular 
Mental  
Nil 
37 
20 
9 
2 
41 
16 
0 
29.6 
16 
7.2 
1.6 
32.8 
12.8 
0 
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3.1.6. Level of Haemoglobin 
Most patients were anaemic with haemoglobin level of <10 g/dL 83 (66.4%) and 10.1 g/dL 
41 (32.8%). Only 0ne patient (0.8%) had haemoglobin of >12 g/dL. (Table 10) 
 
Table 10: Level of Haemoglobin 
Haemoglobin (g/dL) 
 
Number of patients Percentage (%) 
<10             
 
10.1             
 
>12                   
83 
 
41 
 
1 
66.4 
 
32.8 
 
0.8 
 
 
3.1.7. Level of Pre-treatment Calcium 
Majority of patients had severe hypercalcemia with pre-treatment serum calcium level of > 
2.9 mmol/L 77 (61.6%), patients who had serum Ca level between 2.71-2.89 mmol/L were 
28 (22.4%) and those with 2.56-2.70 mmol/L were 20 (16%). Minimum pre-treatment serum 
Ca level was 2.61 mmol/L, maximum 3.97 mmol/L with a mean of 3.0715 +/- SD 0.34918 
mmol/L (Table 11). 
 
Table 11: Level of Pre-treatment Calcium 
Pre-treatment  
Calcium (mmol/L) 
   Number of patients Percentage (%) 
 
2.56-2.70       
  
2.71-2.89    
                  
≥2.9                               
              
              20  
 
              28  
 
              77  
 
16 
 
22.4 
 
61.6 
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3.1.8. Electrolyte and renal function tests 
Serum sodium and potassium, both available for all patients, were Mean 137 mmol/L +/- 
7.690 SD and 4.150 mmol/L +/- 0.4965 SD respectively. The mean urea and creatinine were 
8.2323 mmol/L +/-3.6051 and 103.363.5 mmol/L +/-40.664 SD respectively (Table 12). 
Table 12: Electrolyte and renal function tests  
 Minimum Maximum Mean Std. Deviation 
HB 
Na2+ 
Ca2+ 
K+ 
Urea 
Creatinine 
3.4 
120 
2.61 
3.2 
4.0 
48 
12.1 
149 
3.97 
5.2 
18.1 
265 
9.182 
137.02 
3.0689 
4.150 
8.232 
103.36 
1.7931 
7.690 
0.35329 
0.4965 
3.6051 
40.664 
 
3.2. Treatment and Outcome  
3.2.1. Treatment modalities given 
One hundred and four patients (83.2%) received hydration + bisphosphonates and 
21(16.8%) of patients received hydration alone, non-received haemodialysis (Table 13). 
Zoledronic acid was the bisphosphonates used in 95% of patients. 
 
Table 13: Treatment modalities given 
Treatment  Number of patients 
 
Percentage (%) 
Hydration alone   
 
Hydration +bisphosphonate  
  
Haemodialysis 
 
Other 
21 
 
104 
 
0 
 
0 
16.8 
 
83.2 
 
0 
 
0 
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Overall Improvement in calcium with 
hydration alone 
Improvement in calcium with hydration + 
bisphosphonates.                 
 
At 1 week (p=0.00)                                                   At 1 week (p=0.00)                                                   
At 1 month (p=0.00 )                                                 At 1 month (p=0.00) 
 
3.2.2. Post treatment levels of Calcium 
1 week post treatment majority of patients had ≤2.55 mmol/L Serum level of Calcium 81 
(64.8%), 11 patients (8.8%) had serum level of calcium 2.56-2.71 mmol/L, 23 patients 
(18.4%) had serum calcium between 2.71-2.89 mmol/L and only 10 patients (8.0%) had 
serum level of calcium ≥ 2.9 mmol/L (Table 14). The corrected serum calcium was 2.4770 ± 
0.34512 mmol/L one week after treatment. 
1 month post treatment majority of patient’s 99 (79.2%) remains to have normal serum 
level of calcium ≤ 2.55 and only about 11 (8.8%) patients had ≥ 2.9 mmol/L (Table 15). 
 
Table 14: Post treatment level of calcium (1 week)  
Calcium (mmol/L) Number of patients Percentage (%) 
≤2.55                                                                     
2.56-2.70                           
2.71-2.89                     
≥2.9                               
81
11 
23  
10  
64.8 
8.8 
18.4 
8.0 
 
 
Table 15: Post treatment level of calcium (1 month) 
Calcium (mmol/L) Number of patients Percentage (%) 
≤2.55 
2.56-2.70                           
2.71-2.89                     
≥2.9                               
99 
12  
3  
11  
79.2 
9.6 
2.4  
8.8 
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3.2.3. Symptom relief 
Most patients had symptoms relief after the treatment 93 (74.4%) after one week and 115 
(92%) after 1 month (Table 16). 
Table 16: Symptom relief 
   No. at 1 week (%) No. at 1 month (%) 
Yes 
No 
93 (74.4) 
32 (25.6) 
115 (92) 
10 (8) 
  
3.2.4. Time to relapse after treatment 
 The time to relapse was between 3.28-56 days (mean 34.0518 +/- 12.28215 SD) after 
treatment of hypercalcemia (Table 17). 
 
Table 17: Time to relapse 
 
 Minimum Maximum Mean Std. Deviation 
Time to relapse (Days) 3.28 56.00 34.0518 12.28215 
 
3.3. Treatment of primary malignancy 
Majority of patients were receiving Radiation alone 72 (57.6%) as sole treatment modality 
for their primary cancer. Thirty seven (29.6%) patients were receiving chemotherapy then 
Radiotherapy and 15 (12.0%) concurrent chemo-radiation therapy (Table 18). 
Table 18: Treatment of primary malignancy 
Treatment  Number of patients Percentage (%) 
Radiation 
Surgery +radiation  
Chemotherapy then RT 
Conc. Chemo+radiation 
72  
1  
37  
15  
57.6 
0.8 
29.6 
12.0 
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3.4. Toxicities to bisphosphonates 
Side effects to bisphosphonates were mainly gastrointestinal: Nausea/vomiting 42 (33.6%) 
patients, Constipation 14 (11.2%), abdominal pain 13 (10.4), Diarrhoea 11 (8.8) and anorexia 
1 (0.8) patients. Other toxicities reported were fever 12 (9.6%) patients and hypocalcemia 
14 (11.2%). Eighteen patients (14.4%) did not report any side effect to treatment (Table 19). 
Table 19: Toxicities to bisphosphonates 
 
Toxicity Number of patients Percentage (%) 
Nil 
Fever 
Nausea/vomiting 
Constipation 
Diarrhoea 
Abdominal pain 
Anorexia 
Hypocalcemia 
18 
12  
42  
14  
11  
13  
1  
14  
14.4 
9.6 
33.6 
11.2 
8.8 
10.4 
0.8 
11.2 
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3.5. Treatment versus Pre-treatment Calcium level 
Fourteen (58%) patients with pre-treatment calcium level of 2.56-2.70 mmol/L received 
hydration alone and 76 (98%) of patients with serum pre-treatment calcium of ≥ 2.9 mmol/L 
were treated with hydration + bisphosphonates (P=0.00) (Table 20).                                                      
Table 20: Treatment versus pre-treatment Calcium level  
Calcium level 
(mmol/L) 
2.56-2.70                           2.71-2.89                     ≥2.9                               Total 
Hydration 
Hydration+ 
bisphosphonates 
Total 
14 
10 
24 
6 
18 
24 
1 
76 
77 
21 
104 
125 
P=0.00 
 
3.6. Diagnosis versus pre-treatment calcium level 
Table 21: Diagnosis versus pre-treatment calcium level 
Site 2.56-2.70  
mmol/L                        
2.71-2.89 
mmol/L           
≥2.9 
mmol/L                               
No. of patients 
Lung 
Breast 
Head and Neck 
Multiple 
Myeloma 
Gynae 
Prostate 
GIT 
Others 
0 
4 
8 
2 
3 
2 
2 
3 
0 
2 
6 
2 
3 
6 
2 
3 
3 
11 
9 
1 
25 
11 
8 
9 
3 
17 
23 
5 
31 
19 
12 
15 
P=0.174 
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CHAPTER FOUR 
4.0. Discussion 
This was a retrospective descriptive study, 125 patients who were admitted at the Radiation 
oncology ward CMJAH for hypercalcemia management from January 2012 to December 
2015, were analysed. 
Mean age was 52.31 years ± 11.388 SD, with the youngest patient being 28 years old and 
the oldest being 70 years. Male and female ratio was 1:1. 
The most frequent site of primary cancer diagnosis in patients with hypercalcemia in our 
study were gynaecological malignancies (24.8%), head and neck (18.4%), prostate (15.2%), 
breast cancer (13.6%), gastrointestinal malignancies (9.6%), multiple myeloma (4%) and lung 
cancer (2.4%). The literature states that Lung cancer, breast cancer and multiple myeloma 
have the highest incidence of CIH, accounting for more than 50%, while the disease occurs 
rarely in patients with colorectal and prostate cancer (8, 9). This differs from our study were 
gynaecological, head and neck, prostate and breast cancer were the leading causes of CIH, 
followed by GIT, multiple myeloma and Lung. At CMJAH haematological malignancies, 
metastatic breast and lung are primarily managed by Medical oncology unit, which is 
separated from radiation oncology unit. This can explain the lower number of lung, 
metastatic breast and multiple myeloma in our findings.  
Most patients in our study had metastatic disease (36.8%) and uncontrolled primary disease 
(25.6%) compared to primary controlled disease (37.6%). Bone metastases were present in 
(41%) patients. This correspond with the literature which shows Cancer induced 
hypercalcemia (CIH) is particularly common in patients with advanced cancer and is an 
indicator of poor prognosis with a mean survival rate of 2-3 months except in patients with 
multiple myeloma and breast cancer (3, 11). The extent of metastatic bone disease 
correlates poorly with both the occurrence and severity of CIH (46).   
All patients presented with symptoms related to hypercalcemia. Majority of patients had 
severe hypercalcemia with pre-treatment serum calcium level of > 2.9 mmol/L (61.6%) and 
the mean serum calcium level was 3.0715 mmol/L. The finding in our study that all patients 
were symptomatic is likely because of their higher serum calcium levels. This is supported by 
the medical literature that states that serum calcium levels exceeding 3.0 mmol/L are often 
symptomatic (2). 
Neuromuscular symptoms were the leading symptom for hypercalcemia, followed by 
nausea/vomiting, polyuria, mental and polydipsia. Nausea and anorexia were the second 
leading symptoms, which are also well described in the medical literature as symptoms of 
hypercalcemia (43). 
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Most patients in our study were anaemic with haemoglobin level of <10 g/dL 83 (66.4%), 
only one patient (0.8%) had haemoglobin of >12 g/dL. This can be explained by their chronic 
and advanced malignant diseases.  
A significant proportion of patients with Cancer induced hypercalcemia had concurrent 
other electrolyte disorders in the literature. Cancer induced Hypercalcaemia patients had 
increased serum urea and creatinine levels, a higher urea/creatinine ratio, and a higher rate 
of acid-base disorders, but lower serum albumin, potassium, chloride, phosphorus, and 
magnesium concentrations than those found in the control subjects (45). Our results 
showed serum sodium and potassium were Mean 137 mmol/L +/- 7.690 SD and 4.150 
mmol/L +/- 0.4965 SD. The mean urea and creatinine were 8.2323.5 mmol/L +/-3.6051 and 
103.363.5 mmol/L +/-40.664 SD respectively which did not match with the literature. 
In our study, all patients received standard therapy for acute hypercalcemia. Patients with 
higher serum calcium received more calcium lowering agents, and non-received 
haemodialysis. One hundred and four patients (83.2%) received hydration + 
bisphosphonates and 21(16.8%) of patients received hydration alone. Fifty eighty percent of 
patients with pre-treatment serum calcium of ≤2.70 mmol/L received hydration alone and 
(98.7%) of patients with pre-treatment serum calcium level of ≥2.9 mmol/L received 
hydration + bisphosphonates as a treatment modality (p=0.00). Zoledronic acid was used in 
95% of patients who received hydration + bisphosphonates as mode of treatment.  
The response to treatment after one week was (73.6%) patients and (88.8%) after one 
month. The mean corrected serum calcium was 2.5 mmol/L one week after treatment 
(P=0.00). This correspond with the literature that 70-100% response rates in CIH patients 
who were treated with hydration + bisphosphonates (47, 48, 49). Most patients had 
symptoms relief (74.4%) one week and (92%) one month after treatment. 
The time to relapse in this study was 34 days after treatment of hypercalcemia, similar to 
the time to relapse of zoledronic acid 30-40 days (50).  
Majority of patients were receiving Radiation alone (57.6%) as sole treatment modality for 
their primary cancer. Thirty seven (29.6%) patients were receiving chemotherapy and 
(12.0%) concurrent chemo-radiation therapy.  
Side effects to bisphosphonates were mainly gastrointestinal: Nausea/vomiting (33.6%) 
patients, Constipation (11.2%), abdominal pain (10.4%), Diarrhoea (8.8%) and anorexia 
(0.8%) patients. Other toxicities reported were fever (9.6%) patients and hypocalcemia 
(11.2%). Eighteen patients (14.4%) did not report any side effect to treatment. Our results 
correspond to toxicities of bisphosphonates most reported in the literature (28). 
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4.1. Study limitations 
The limitations of this study include  
• It is a single centre study conducted in a radiation oncology ward so the results may 
not be representative of all oncology units. 
• It is a retrospective study. 
• There is non-standardized documentation (all signs and symptoms of hypercalcemia 
were likely not documented for each patient). 
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4.2. Conclusion 
Hypercalcemia of malignancy remains to be a common finding in patients with advanced 
stage cancers. The most frequent site of primary cancer diagnosis in patients with 
hypercalcemia in our study were gynaecological malignancies, head and neck, prostate, 
breast cancer, gastrointestinal malignancies, multiple myeloma and lung cancer. 
Hypercalcemia of malignancy usually presents with markedly elevated calcium levels and 
patients are therefore usually symptomatic.  
Our results show that in patients with malignancy induced hypercalcemia presents with 
symptoms such as neuromuscular symptoms, gastrointestinal symptoms such as nausea or 
disorientation, or a change in mental status. 
For acute management of hypercalcemia, rehydration is the mainstay of treatment because 
all patients tend to have dehydration. Bisphosphonates are potent calcium lowering agents, 
but they are contraindicated in patients with declined renal function. 
In our study, all patients received standard therapy for acute hypercalcemia. Patients with 
higher serum calcium received calcium lowering agents. Ninety two patients (73.6%) 
responded to treatment after one week and 111 (88.8%) patients remains to have normal 
serum one month after treatment. 
Common bisphosphonates toxicities noted were mainly gastrointestinal: Nausea/vomiting, 
constipation, abdominal pain, diarrhoea and anorexia. Other toxicities reported were fever 
and hypocalcaemia.   
 
4.3. Recommendations 
 Emergency physicians/ oncologists should measure serum calcium and albumin 
levels in all patients with underlying malignancy present with unspecific symptoms 
such as weakness, gastrointestinal symptoms such as nausea or disorientation, or a 
change in mental status. 
 Hypercalcemic crisis is a life-threatening emergency. Aggressive IV hydration and 
bisphosphonate therapy should be used in management of symptomatic CIH or 
patient with a serum calcium level of > 2.56 mmol/L to alleviate the clinical 
manifestations of hypercalcaemic disorders.  
 Patients with advanced underlying kidney disease and refractory severe 
hypercalcemia should be considered for denosumab therapy and haemodialysis. 
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Appendix A: Proforma (Data collection form) 
                                                             PROFORMA 
 
 
Code number 
 
 
 
Suitability 
 
 
1= Yes 2= No 
Age (years) 
 
 
 
Sex 
 
 
1= Male 2= Female 
Diagnosis of malignancy 
 
 
 
1= 
Lung 
2= 
Breast 
3= 
Head 
and 
neck 
4= 
Multiple 
Myeloma 
5= 
Gynae 
6=Pros
tate 
7= 
GIT 
8= 
Other
s 
Presentation of primary 
cancer   
 
 
 
1= Primary    
      Controlled 
2= Primary  
    Uncontrolled 
3= Metastatic disease 
Bone Metastasis    
 
 
1= Present 2= Absent 
Clinical presentation     
 
 
1= Nausea &  
     Vomiting 
 
 
2= Polyuria 3= Polydipsia 
4 = Constipation 
 
 
5= Neuromuscular 6= Mental 
7= Nil   
 
 
  
Investigations done 
 
 
 
HB Na2+ K+ Ca2+ Urea  Creatinine 
Pre-treatment serum 
(baseline) corrected Ca in 
mmol/l 
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Treatment of 
Hypercalcaemia 
 
 
1= Hydration 
     alone 
2= Hydration +    
      Bisphosphonates  
3= Hydration +  
      Steroids 
1  week  post treatment 
corrected Ca2+    (mmol/l) 
 
 
 
1 month post treatment 
corrected Ca2+   (mmol/l) 
 
 
 
 
Symptom relief at 1 week 
 
 
 
1= Yes 2= No 
Symptom relief at 1 month 
 
 
 
1= Yes 2= No 
Relapse  
 
 
 
1= Yes  2= No 
Time to relapse (days) 
 
 
 
 
Subsequent treatment after 
relapse    
 
 
1= Hydration 
      Alone  
2= Hydration +    
     Bisphosphonates 
3= Hydration +  
     Steroids 
Treatment of Primary 
tumour        
 
 
1= 
Surgery 
2= 
Radiation 
3= Surgery 
+ Radiation   
4= Chemo    5. Concurrent      
  Then RT 
                        ChemoRT 
Acute toxicity (Side effects) 
of Bisphosphonates 
0= Nil 
 
 
1= Fever 2= Nausea &Vomiting 
3= Constipation 
 
 
4= Dyspnoea 5= Diarrhoea 
6= Abdominal  
 
      pain 
7= Anorexia 8= Hypocalcaemia 
9= Others 
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